Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | LIMK2 | P53671 | 3/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.44 |
| ▸ | BACE1 | P56817 | 3/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202183 | 0.96 | F2 (0.51) | F2LIMK2TGFBR1HTR6ADRB3 | |
| SCHEMBL2196090 | 0.80 | F2 (0.53) | F2TGFBR1HTR6 | |
| SCHEMBL15946028 | 0.79 | HTR6 (0.50) | LIMK2HTR6ADRB3PTGESADRB2 | |
| SCHEMBL3132483 | 0.77 | HTR6 (0.58) | HTR6ADRB3ALDH1A1GAAHPGD | |
| SCHEMBL3134261 | 0.76 | ADRB3 (0.47) | LIMK2HTR6ADRB3PTGESADRB2 | |
| SCHEMBL14020393 | 0.74 | HTR6 (0.52) | HTR6ADRB3ADRB2ADRB1ALDH1A1 | |
| SCHEMBL4605486 | 0.74 | HTR6 (0.52) | HTR6ADRB3ADRB2ADRB1ALDH1A1 | |
| SCHEMBL27840648 | 0.74 | HTR6 (0.52) | HTR6ADRB3PTGESADRB2ADRB1 | |
| SCHEMBL4605482 | 0.74 | HTR6 (0.52) | HTR6ADRB3ADRB2ADRB1ALDH1A1 | |
| SCHEMBL4793028 | 0.74 | HTR6 (0.52) | HTR6ADRB3ADRB2ADRB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-05-26 | — | — | US | disclosed |
| US-9193669-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-08-14 | — | — | US | disclosed |
| EP-2340242-A2 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2011-07-06 | — | — | EP | disclosed |
| WO-2010048332-A2 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | F2 4045/4885LIMK2 1881/4885TGFBR1 4218/4885 |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | F2 4045/4885LIMK2 1881/4885TGFBR1 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.